Neurocognition After Radiotherapy in CNS- and Skull-base Tumors
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversitaire Ziekenhuizen KU Leuven
About this trial
The goal of this multicenter prospective longitudinal study is to study the long-term impact of multimodal treatment (chemotherapy, radiotherapy and surgery) in adult brain and base of skull tumors on neurocognitive functioning.
All included patients will complete a self-report inventory (subjective cognitive functioning, QoL, confounders), a cognitive test battery, an advanced MR at multiple timepoints. Moreover, toxicity will be scored according to the CTCAEv5.0 in these patients over time.
Eligibility criteria
Qualifiers
Adult patients (≥ 18 years at the time of diagnosis) with a primary brain or base of skull tumour, who are amenable for conventionally fractionated radiotherapy (photon or proton irradiation)
Disqualifiers
Incompletely resected IDH-wild-type glioma
Completely resected IDH-wild-type and MGMT-promotor unmethylated glioma
grade III meningioma
H3K27M+ midline glioma
Trial design
Treatments tested in this trial
- Neurocognitive tests: WAIS digit span, HVLT-R, COWAT, MOCA, WAIS digit symbol substitution, TMT A&B, Stroop Color Word Test
- MRI
- Questionnaires: EORTC QLQ C30 & BN20, STAI, CFQ, BDI-II, BRIEF-A, FACIT-F, PSQI
- Toxicity scoring
Treatment groups
120 Participants
are divided into 1 treatment groupSponsors and collaborators
Universitaire Ziekenhuizen KU Leuven
Lead sponsor
University Hospital, Ghent
Collaborator
Gasthuis Zusters Antwerpen
Collaborator
Source ClinicalTrials.gov